Combination of Methionine, Inositol, Choline and Vitamin B12. These are lipotropic agents that help breakdown fat, during metabolism, by increasing overall energy. They are also closely related to B vitamins and are usually injected together as part of the same treatment injection cycle.

GET YOUR SAVINGS CARD HERE ~https://www.enrollment.zepbound.lilly.com/enroll/checkEnrollment ~ Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist. It works by acting like GLP-1 and GIP, two hormones that your gut releases into the body. These hormones are thought to play a role in controlling your appetite, by making you feel more full and less hungry.

Combination of naltrexone (opioid antagonist used for addictions) and bupropion (used for depression and smoking cessation). Some patients may lose 5 -10% of body weight.

Combination of phentermine (sympathomimetic amine, anti-obesity drug) and topiramate (used to treat seizures and migraine headaches). DEA Schedule IV drug. Some patients may lose an average of 5 –10% of body weight.

Sympathomimetic amine approved in 1959. It is a DEA Schedule IV stimulant agent approved for short-term use (12 weeks). Some patients may lose about 5% of body weight.

Gastrointestinal lipase inhibitor that impairs digestion of dietary fat.Lower doses are approved over-the-counter. Some patients may lose about 5% of body weight.

Glucagon-like peptide-1 receptor agonist that is an injectable drug. At lower doses (1.8 mg per day), liraglutide is indicated to lower blood sugar among patients with type 2 diabetes mellitus. Liraglutide 3.0 mg per day is approved for treatment of obesity. Some patients may lose 5 –10% of body weight, especially with the liraglutide higher dose.

Glucagon-like peptite-1 receptor agonist that is an injectable drug. Semaglutideis used at doses up to 2.0 mg weekly for type 2 diabetes. Semaglutide 2.4 mg weekly is approved for treatment of obesity. Average weight loss at one year is 16%.